Patents Assigned to Amrad Operations Pty. Ltd.
-
Publication number: 20080260729Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.Type: ApplicationFiled: August 2, 2005Publication date: October 23, 2008Applicant: Amrad Operations Pty. LtdInventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
-
Publication number: 20080009447Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signaling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions, the amelioration of symptoms of which, are facilitated by an over-expression of a gene encoding a suppressor of cytokine signaling molecule. The present invention further contemplates agents useful for the prophylaxis and/or treatment of such conditions in mammals including humans.Type: ApplicationFiled: July 9, 2007Publication date: January 10, 2008Applicant: Amrad Operations Pty LtdInventors: Andrew Nash, Pino Maccarone, Paul Egan, Ian Wicks
-
Patent number: 7128922Abstract: The present invention relates generally to compositions and more particularly to compositions comprising leukaemia inhibitory factor (hereinafter referred to as “LIF”) or derivative or homologues thereof. The compositions of the present invention are particularly useful as compositions which exhibit enhanced stability and/or which exhibit reduced aggregation and/or reduced deamidation of LIF, its derivatives or other active ingredients.Type: GrantFiled: November 26, 1998Date of Patent: October 31, 2006Assignee: Amrad Operations Pty LtdInventors: Susan Ann Charman, Anthony John Radford
-
Publication number: 20060051842Abstract: The present invention relates generally to novel haemopoietin receptors, or components or parts thereof and to a method for cloning genetic sequences encoding same. More particularly, the subject invention is directed to recombinant or synthetic haemopoietin receptors or components or parts thereof. The receptor molecules or components or parts thereof and their genetic sequences of the present invention are useful in the development of a wide range agonists, antagonists and therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: August 16, 2005Publication date: March 9, 2006Applicant: Amrad Operations Pty, Ltd.Inventor: Douglas Hilton
-
Patent number: 7002000Abstract: The present invention relates generally to novel haemopoietin receptors, or components or parts thereof and to a method for cloning genetic sequences encoding same. More particularly, the subject invention is directed to recombinant or synthetic haemopoietin receptors or components or parts thereof. The receptor molecules or components or parts thereof and their genetic sequences of the present invention are useful in the development of a wide range of agonists, antagonists and therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: March 22, 2000Date of Patent: February 21, 2006Assignee: AMRAD Operations Pty. Ltd.Inventor: Douglas James Hilton
-
Patent number: 6930118Abstract: The invention provides aminoalkylindole compounds of Formula (I), wherein R1-R5, n and p are as described. Also provided are compositions containing compounds of Formula (I) and the use of compounds of Formula (I) in modulating the activity of a cannabinoid receptor in a subject.Type: GrantFiled: November 2, 2001Date of Patent: August 16, 2005Assignee: Amrad Operations Pty. Ltd.Inventors: Peter Gerard Moloney, Alan Duncan Robertson
-
Patent number: 6911530Abstract: The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: October 13, 2000Date of Patent: June 28, 2005Assignee: Amrad Operations, Pty., Ltd.Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 6870031Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: GrantFiled: December 7, 2001Date of Patent: March 22, 2005Assignee: Amrad Operations Pty. Ltd.Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
-
Publication number: 20050058645Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor ?1 chain (IL-13R?1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R?1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R?1/ligand interaction is also provided.Type: ApplicationFiled: May 20, 2004Publication date: March 17, 2005Applicant: AMRAD OPERATIONS PTY. LTD.Inventors: Felicity Dunlop, Manuel Baca, Andrew Nash, Louis Fabri, Douglas Hilton, Nicos Nicola
-
Publication number: 20040043000Abstract: The present invention relates generally to a method for controlling fertility and/or modulating the maintenance of pregnancy in animals. The present invention further provides an animal model useful for screening for therapeutic agents to treat infertility, to prevent or reduce spontaneous abortion and/or as contraceptive agents in animals.Type: ApplicationFiled: September 10, 2003Publication date: March 4, 2004Applicant: Amrad Operations, Pty. Ltd.Inventors: Lorraine Grace Robb, Harshal Hanumant Nandurkar, Colin Glenn Begley
-
Publication number: 20040005671Abstract: The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B.Type: ApplicationFiled: May 16, 2003Publication date: January 8, 2004Applicant: Amrad Operations Pty Ltd.Inventors: Andrew Nash, Giuseppe Maccarone, Pierre David Scotney
-
Patent number: 6669934Abstract: The present invention relates to a method for modulating fertility in an animal by administering an effective amount of IL-11 or derivatives or homologues thereof or an effective amount of an agonist or antagonist of the interaction between IL-11 and IL-11R&agr;.Type: GrantFiled: August 27, 1999Date of Patent: December 30, 2003Assignee: Amrad Operations, Pty. Ltd.Inventors: Lorraine Grace Robb, Harshal Hanumant Nandurkar, Colin Glenn Begley
-
Patent number: 6479274Abstract: The present invention related generally to novel molecules and more particularly novel proteinaceous molecules involved in or associated with regulation of cell activities and/or viability. The present invention is particularly directed to novel serine proteinases and a novel kinase and to derivatives, agonists and antagonists thereof. In one embodiment, the present invention provides a novel serine proteinase, referred to herein as “HELA2” or “testisin”, which has roles in spermatogenesis, in suppressing testicular cancer and as a marker for cancers.Type: GrantFiled: February 13, 1998Date of Patent: November 12, 2002Assignee: Amrad Operations Pty., Ltd.Inventors: Toni Marie Antalis, John David Hooper
-
Patent number: 6414128Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: GrantFiled: September 17, 1998Date of Patent: July 2, 2002Assignee: Amrad Operations Pty. Ltd.Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
-
Patent number: 6274708Abstract: The present invention relates generally to novel haemopoietin receptors, or components or parts thereof and to a method for cloning genetic sequences encoding same. More particularly, the subject invention is directed to recombinant or synthetic haemopoietin receptors or components or parts thereof. The receptor molecules or components or parts thereof and their genetic sequences of the present invention are useful in the development of a wide range of agonists, antagonists and therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: December 20, 1996Date of Patent: August 14, 2001Assignee: AMRAD Operations Pty Ltd.Inventor: Douglas James Hilton
-
Patent number: 6265211Abstract: The present invention is directed generally to an isolated nucleic acid molecule encompassing a neocentromere or a functional derivative thereof or a latent, synthetic or hybrid form thereof and its use inter alia in developing a range of eukaryotic artificial chromosomes including mammalian (e.g. human) and non-mammalian artificial chromosomes. Such artificial chromosomes are useful in a range of genetic therapies.Type: GrantFiled: May 13, 1998Date of Patent: July 24, 2001Assignee: AMRAD Operations Pty. Ltd.Inventors: Kong-Hong Andy Choo, Desiree Du Sart, Michael Robert Cancilla
-
Patent number: 6200966Abstract: The invention relates to compositions which modulate airway remodelling comprisiing the sterioid 2-methyoxy-estradiol or analogues thereof, for administration by inhalation.Type: GrantFiled: June 11, 1999Date of Patent: March 13, 2001Assignee: Amrad Operations Pty. Ltd.Inventor: Alastair George Stewart
-
Patent number: 6043069Abstract: The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.Type: GrantFiled: March 26, 1997Date of Patent: March 28, 2000Assignee: Amrad Operations Pty. Ltd.Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
-
Patent number: 5962445Abstract: The invention relates to use of steroids or steroid analogues in the treatment of chronic and acute inflammation of the airways, particularly asthmatic conditions. It also relates to compounds and compositions which modulate airway remodelling. In a preferred embodiment, the steroid is 2-methoxyoestradiol.Type: GrantFiled: May 9, 1997Date of Patent: October 5, 1999Assignee: Amrad Operations Pty Ltd.Inventor: Alastair George Stewart